{
    "clinical_study": {
        "@rank": "65652", 
        "brief_summary": {
            "textblock": "To evaluate the effectiveness and safety of amphotericin B plus flucytosine\n      (5-fluorocytosine) compared to amphotericin B alone for a first episode of acute\n      cryptococcal meningitis in AIDS patients, and to compare the effectiveness and safety of\n      fluconazole versus itraconazole.\n\n      At least 10 percent of patients with a low CD4 count and HIV infection will develop\n      meningitis due to Cryptococcus neoformans. More effective treatments than the standard\n      therapy need to be explored."
        }, 
        "brief_title": "A Randomized Double Blind Protocol Comparing Amphotericin B With Flucytosine to Amphotericin B Alone Followed by a Comparison of Fluconazole and Itraconazole in the Treatment of Acute Cryptococcal Meningitis", 
        "completion_date": {
            "#text": "September 1997", 
            "@type": "Actual"
        }, 
        "condition": [
            "Meningitis, Cryptococcal", 
            "HIV Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "Meningitis", 
                "Meningitis, Cryptococcal"
            ]
        }, 
        "detailed_description": {
            "textblock": "At least 10 percent of patients with a low CD4 count and HIV infection will develop\n      meningitis due to Cryptococcus neoformans. More effective treatments than the standard\n      therapy need to be explored.\n\n      Patients are selected by a randomization process to take amphotericin B intravenously (in\n      the vein), for 14 days, and either placebo (ineffective substance) or flucytosine for 14\n      days. Then patients are again selected by a randomization process to take either (1)\n      fluconazole for a total of 8 weeks plus itraconazole placebo; or (2) itraconazole for a\n      total of 8 weeks plus fluconazole placebo."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Allowed:\n\n          -  Interruption of myelosuppressive therapies and/or administration of erythropoietin,\n             at discretion of investigator, to maintain hemoglobin = or > 7 g/dl.\n\n          -  Adjunctive corticosteroids may be administered during the triazole phase for patients\n             who develop Pneumocystis carinii pneumonia and meet the prescribed criteria.\n\n          -  Hydrocortisone, not to exceed 50 mg/day, during the amphotericin phase.\n\n          -  Aerosolized pentamidine or systemic chemoprophylaxis for Pneumocystis carinii\n             pneumonia should be given to all patients with a CD4 count < 200 cells/mm3.\n\n          -  Antiretroviral drugs (including zidovudine (AZT), didanosine (ddI), dideoxycytidine\n             (ddC)) after patient has tolerated oral triazole for one week (after 3 weeks of study\n             treatment).\n\n          -  Maintenance treatment (except for rifamycins) for other opportunistic infections such\n             as cytomegalovirus (CMV) retinitis, cerebral toxoplasmosis or mycobacterial\n             infections, provided that their hematologic and hepatic values are stable and they\n             meet the entry criteria.\n\n        Concurrent Treatment:\n\n        Allowed:\n\n        - Transfusion, at discretion of investigator, to maintain hemoglobin = or > 7 g/dl.\n\n        Patients must have:\n\n          -  HIV infection.\n\n          -  Primary episode of acute cryptococcal meningitis.\n\n          -  Willing to participate in the study for a full 10 weeks and either be able to give\n             informed consent or have a family member or guardian able to give informed consent.\n\n        Prior Medication:\n\n        Allowed:\n\n        Fluconazole prophylaxis, not exceeding 200 mg/day.\n\n        Risk Behavior:\n\n        Allowed:\n\n        - History of high-risk behavior for HIV infection (bisexual or homosexual men, intravenous\n        drug abusers) and their sexual partners.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following conditions or symptoms are excluded:\n\n          -  Inability to take oral medication (if necessary, flucytosine and flucytosine placebo\n             may be administered via nasogastric tube during the amphotericin phase).\n\n          -  History of hypersensitivity to imidazole or triazole compounds.\n\n          -  Active hepatitis (viral, drug-induced, or other) defined by progressive worsening of\n             hepatic enzymes to grade 3 or 4 toxicity on at least two occasions.\n\n          -  Comatose.\n\n          -  Concurrent CNS disease which, in the opinion of the investigator, would interfere\n             with assessment of response.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Continued treatment with H2 blockers (ranitidine (Zantac), cimetidine (Tagamet),\n             omeprazole (Prilosec), nizatidine (Axid), famotidine (Pepcid)).\n\n          -  Antacids and didanosine (ddI) within 2 hours of triazole administration.\n\n          -  Rifampin, rifabutin (Ansamycin), and other rifamycin derivatives, phenytoin\n             (Dilantin), phenobarbital, or carbamazepine (Tegretol).\n\n          -  Other systemic antifungal agents.\n\n        Prior Medication:\n\n        Excluded:\n\n          -  Amphotericin, > 1 mg/kg, or fluconazole or ketoconazole, > 1200 mg, as prior\n             treatment for current primary episode of acute cryptococcal meningitis or treatment\n             started for this episode more than 72 hours prior to enrollment into study.\n\n          -  Phenytoin (Dilantin), carbamazepine (Tegretol), phenobarbital, rifabutin (Ansamycin),\n             rifampin or other rifamycins within the last 15 days.\n\n        Patients may not have:\n\n          -  Inability to take oral medication (if necessary, flucytosine and flucytosine placebo\n             may be administered via nasogastric tube during the amphotericin phase).\n\n          -  History of hypersensitivity to imidazole or triazole compounds.\n\n          -  Active hepatitis.\n\n          -  Patients who are comatose.\n\n          -  Concurrent CNS disease which, in the opinion of the investigator, would interfere\n             with assessment of response."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "13 Years"
        }, 
        "enrollment": "400", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00000639", 
            "org_study_id": "ACTG 159", 
            "secondary_id": [
                "FDA 235A", 
                "MSG Study 17", 
                "11134"
            ]
        }, 
        "intervention": [
            {
                "intervention_name": "Itraconazole", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Flucytosine", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Fluconazole", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Amphotericin B", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Amphotericin B", 
                "Liposomal amphotericin B", 
                "Fluconazole", 
                "Flucytosine", 
                "Itraconazole", 
                "Hydroxyitraconazole"
            ]
        }, 
        "keyword": [
            "AIDS-Related Opportunistic Infections", 
            "Meningitis", 
            "Cryptococcosis", 
            "Drug Evaluation", 
            "Drug Therapy, Combination", 
            "Fluconazole", 
            "Flucytosine", 
            "Acquired Immunodeficiency Syndrome", 
            "Amphotericin B", 
            "Brain Diseases"
        ], 
        "lastchanged_date": "March 29, 2012", 
        "link": [
            {
                "description": "Click here for more information about Fluconazole", 
                "url": "http://www.aidsinfo.nih.gov/DrugsNew/DrugDetailNT.aspx?MenuItem=Drugs&Search=On&int_id=5"
            }, 
            {
                "description": "Click here for more information about Amphotericin B", 
                "url": "http://www.aidsinfo.nih.gov/DrugsNew/DrugDetailNT.aspx?MenuItem=Drugs&Search=On&int_id=6"
            }, 
            {
                "description": "Click here for more information about Itraconazole", 
                "url": "http://www.aidsinfo.nih.gov/DrugsNew/DrugDetailNT.aspx?MenuItem=Drugs&Search=On&int_id=44"
            }
        ], 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90033"
                    }, 
                    "name": "USC CRS"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94110"
                    }, 
                    "name": "Ucsf Aids Crs"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33136"
                    }, 
                    "name": "Univ. of Miami AIDS CRS"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Honolulu", 
                        "country": "United States", 
                        "state": "Hawaii"
                    }, 
                    "name": "Univ. of Hawaii at Manoa, Leahi Hosp."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60611"
                    }, 
                    "name": "Northwestern University CRS"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Indianapolis", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46202"
                    }, 
                    "name": "Indiana Univ. School of Medicine, Infectious Disease Research Clinic"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Indianapolis", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46202"
                    }, 
                    "name": "Methodist Hosp. of Indiana"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New Orleans", 
                        "country": "United States", 
                        "state": "Louisiana", 
                        "zip": "70112"
                    }, 
                    "name": "Tulane Med. Ctr. - Charity Hosp. of New Orleans, ACTU"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02114"
                    }, 
                    "name": "Massachusetts General Hospital ACTG CRS"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02215"
                    }, 
                    "name": "Beth Israel Deaconess Med. Ctr., ACTG CRS"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02118"
                    }, 
                    "name": "Bmc Actg Crs"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St Louis", 
                        "country": "United States", 
                        "state": "Missouri"
                    }, 
                    "name": "St. Louis ConnectCare, Infectious Diseases Clinic"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Louis", 
                        "country": "United States", 
                        "state": "Missouri"
                    }, 
                    "name": "Washington U CRS"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Buffalo", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "14215"
                    }, 
                    "name": "SUNY - Buffalo, Erie County Medical Ctr."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10021"
                    }, 
                    "name": "Cornell University A2201"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10003"
                    }, 
                    "name": "Beth Israel Med. Ctr. (Mt. Sinai)"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "14642"
                    }, 
                    "name": "Univ. of Rochester ACTG CRS"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chapel Hill", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27599"
                    }, 
                    "name": "Unc Aids Crs"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Charlotte", 
                        "country": "United States", 
                        "state": "North Carolina"
                    }, 
                    "name": "Carolinas HealthCare System, Carolinas Med. Ctr."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Greensboro", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27401"
                    }, 
                    "name": "Regional Center for Infectious Disease, Wendover Medical Center CRS"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cincinnati", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45267"
                    }, 
                    "name": "Univ. of Cincinnati CRS"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "43210"
                    }, 
                    "name": "The Ohio State Univ. AIDS CRS"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19104"
                    }, 
                    "name": "Hosp. of the Univ. of Pennsylvania CRS"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pittsburgh", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "15213"
                    }, 
                    "name": "Pitt CRS"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Randomized Double Blind Protocol Comparing Amphotericin B With Flucytosine to Amphotericin B Alone Followed by a Comparison of Fluconazole and Itraconazole in the Treatment of Acute Cryptococcal Meningitis", 
        "overall_official": [
            {
                "last_name": "van der Horst C", 
                "role": "Study Chair"
            }, 
            {
                "last_name": "Saag M", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "N/A", 
        "reference": [
            {
                "PMID": "9203426", 
                "citation": "van der Horst CM, Saag MS, Cloud GA, Hamill RJ, Graybill JR, Sobel JD, Johnson PC, Tuazon CU, Kerkering T, Moskovitz BL, Powderly WG, Dismukes WE. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med. 1997 Jul 3;337(1):15-21."
            }, 
            {
                "PMID": "8722838", 
                "citation": "Powderly WG. Recent advances in the management of cryptococcal meningitis in patients with AIDS. Clin Infect Dis. 1996 May;22 Suppl 2:S119-23. Review. PubMed PMID: 8722838."
            }, 
            {
                "citation": "Powderly WG, Tuazon C, Cloud GA, Saag MS, Van Der Horst C. Serum and CSF cryptococcal antigen in management of cryptococcal meningitis in AIDS. Conf Retroviruses Opportunistic Infect. 1997 Jan 22-26;4th:66 (abstract no 6)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00000639"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "National Institute of Allergy and Infectious Diseases (NIAID)", 
        "sponsors": {
            "collaborator": {
                "agency": "Washington University School of Medicine", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "National Institute of Allergy and Infectious Diseases (NIAID)", 
                "agency_class": "NIH"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2012"
    }, 
    "geocoordinates": {
        "Beth Israel Deaconess Med. Ctr., ACTG CRS": "42.358 -71.06", 
        "Beth Israel Med. Ctr. (Mt. Sinai)": "40.714 -74.006", 
        "Bmc Actg Crs": "42.358 -71.06", 
        "Carolinas HealthCare System, Carolinas Med. Ctr.": "35.227 -80.843", 
        "Cornell University A2201": "40.714 -74.006", 
        "Hosp. of the Univ. of Pennsylvania CRS": "39.952 -75.164", 
        "Indiana Univ. School of Medicine, Infectious Disease Research Clinic": "39.769 -86.158", 
        "Massachusetts General Hospital ACTG CRS": "42.358 -71.06", 
        "Methodist Hosp. of Indiana": "39.769 -86.158", 
        "Northwestern University CRS": "41.878 -87.63", 
        "Pitt CRS": "40.441 -79.996", 
        "Regional Center for Infectious Disease, Wendover Medical Center CRS": "36.073 -79.792", 
        "SUNY - Buffalo, Erie County Medical Ctr.": "42.886 -78.878", 
        "St. Louis ConnectCare, Infectious Diseases Clinic": "38.627 -90.199", 
        "The Ohio State Univ. AIDS CRS": "39.961 -82.999", 
        "Tulane Med. Ctr. - Charity Hosp. of New Orleans, ACTU": "29.951 -90.072", 
        "USC CRS": "34.052 -118.244", 
        "Ucsf Aids Crs": "37.775 -122.419", 
        "Unc Aids Crs": "35.913 -79.056", 
        "Univ. of Cincinnati CRS": "39.103 -84.512", 
        "Univ. of Hawaii at Manoa, Leahi Hosp.": "21.307 -157.858", 
        "Univ. of Miami AIDS CRS": "25.789 -80.226", 
        "Univ. of Rochester ACTG CRS": "43.161 -77.611", 
        "Washington U CRS": "38.627 -90.199"
    }
}